BioLineRx (NASDAQ:BLRX) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of BioLineRx (NASDAQ:BLRX) in a research note published on Friday morning. The firm issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright cut their price target on shares of BioLineRx from $21.00 to $9.00 and set a “buy” rating on the stock in a report on Monday, November 25th.

BioLineRx Stock Performance

NASDAQ BLRX opened at $0.27 on Friday. The business’s 50 day moving average price is $0.32 and its 200-day moving average price is $0.52. BioLineRx has a fifty-two week low of $0.19 and a fifty-two week high of $1.58. The company has a market cap of $21.89 million, a P/E ratio of -1.24 and a beta of 1.39. The company has a debt-to-equity ratio of 2.11, a quick ratio of 1.37 and a current ratio of 1.52.

Institutional Trading of BioLineRx

A number of large investors have recently made changes to their positions in the stock. PVG Asset Management Corp purchased a new stake in shares of BioLineRx in the second quarter valued at approximately $70,000. Atria Investments Inc raised its position in BioLineRx by 27.9% during the 3rd quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock valued at $72,000 after purchasing an additional 29,193 shares in the last quarter. Finally, CVI Holdings LLC purchased a new stake in shares of BioLineRx in the 2nd quarter worth $462,000. 1.56% of the stock is owned by hedge funds and other institutional investors.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.